Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors

(2018) Anthony W. Tolcher et al.   MOLECULAR CANCER THERAPEUTICS

Chk1 inhibition as a novel therapeutic strategy in melanoma

(2018) Bor-Jang Hwang et al.   Oncotarget

Targeted Tumor Therapy Remixed—An Update on the Use of Small-Molecule Drugs in Combination Therapies

(2018) Martina Gatzka   Cancers

Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance

(2018) Farzana Ahmed et al.   Frontiers in Oncology

Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017

(2017) Selma Ugurel et al.   EUROPEAN JOURNAL OF CANCER

ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells

(2017) Giulia Cesi et al.   Molecular Cancer

Ras–MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells

(2017) Ho-June Lee et al.   MOLECULAR CANCER THERAPEUTICS

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state

(2017) Mohammad Fallahi‐Sichani et al.   Molecular Systems Biology

Targeted agents and immunotherapies: optimizing outcomes in melanoma

(2017) Jason J. Luke et al.   Nature Reviews Clinical Oncology

Non-kinase targets of protein kinase inhibitors

(2017) Lenka Munoz   NATURE REVIEWS DRUG DISCOVERY

The target landscape of clinical kinase drugs

(2017) Susan Klaeger et al.   SCIENCE

A Computational Approach for Identifying Synergistic Drug Combinations

(2017) Kaitlyn M. Gayvert et al.   PLoS Computational Biology

Talimogene Laherparepvec for the Treatment of Advanced Melanoma

(2016) P. A. Ott et al.   CLINICAL CANCER RESEARCH

Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016

(2016) Claus Garbe et al.   EUROPEAN JOURNAL OF CANCER

Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations

(2016) Lavinia Spain et al.   EXPERT OPINION ON PHARMACOTHERAPY

The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031

(2016) David C. Whiteman et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Cell Cycle Regulation and Melanoma

(2016) Wen Xu et al.   Current Oncology Reports

Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma

(2015) Gry Irene Magnussen et al.   BMC CANCER

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

(2015) Eishu Hirata et al.   CANCER CELL

Chk1 and Wee1 control genotoxic-stress induced G2–M arrest in melanoma cells

(2015) Julio Vera et al.   CELLULAR SIGNALLING

Cell cycle control as a promising target in melanoma

(2015) Belinda Lee et al.   CURRENT OPINION IN ONCOLOGY

Extending kinome coverage by analysis of kinase inhibitor broad profiling data

(2015) Edgar Jacoby et al.   DRUG DISCOVERY TODAY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma

(2015) Christian Posch et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Exploiting replicative stress to treat cancer

(2015) Matthias Dobbelstein et al.   NATURE REVIEWS DRUG DISCOVERY

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model

(2015) Bhagwan Yadav et al.   Computational and Structural Biotechnology Journal

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma

(2015) Rosaria Chilà et al.   Oncotarget

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

(2014) Edward Sausville et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Identification of Aurora Kinase B and Wee1-Like Protein Kinase as Downstream Targets of V600EB-RAF in Melanoma

(2013) Arati Sharma et al.   AMERICAN JOURNAL OF PATHOLOGY

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo

(2013) L. Chaudhuri et al.   HAEMATOLOGICA

Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F

(2013) Karoline Gäbler et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines

(2013) Lifang Xie et al.   MELANOMA RESEARCH

Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors

(2013) Todd M. Pitts et al.   PHARMACOLOGY & THERAPEUTICS

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition

(2012) Amy D Guertin et al.   Cancer Cell International

High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy

(2012) Gry Irene Magnussen et al.   PLoS One

Comprehensive analysis of kinase inhibitor selectivity

(2011) Mindy I Davis et al.   NATURE BIOTECHNOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE